{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T03:04:19Z","timestamp":1740107059859,"version":"3.37.3"},"reference-count":91,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2022,11,2]],"date-time":"2022-11-02T00:00:00Z","timestamp":1667347200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2022,11,2]],"date-time":"2022-11-02T00:00:00Z","timestamp":1667347200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100002322","name":"Coordena\u00e7\u00e3o de Aperfei\u00e7oamento de Pessoal de N\u00edvel Superior","doi-asserted-by":"publisher","award":["001","001"],"award-info":[{"award-number":["001","001"]}],"id":[{"id":"10.13039\/501100002322","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001807","name":"Funda\u00e7\u00e3o de Amparo \u00e0 Pesquisa do Estado de S\u00e3o Paulo","doi-asserted-by":"publisher","award":["2018\/10052-1","2018\/10052-1"],"award-info":[{"award-number":["2018\/10052-1","2018\/10052-1"]}],"id":[{"id":"10.13039\/501100001807","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003593","name":"Conselho Nacional de Desenvolvimento Cient\u00edfico e Tecnol\u00f3gico","doi-asserted-by":"publisher","award":["552120\/2011-1","552120\/2011-1"],"award-info":[{"award-number":["552120\/2011-1","552120\/2011-1"]}],"id":[{"id":"10.13039\/501100003593","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Cancer Res Clin Oncol"],"published-print":{"date-parts":[[2023,7]]},"DOI":"10.1007\/s00432-022-04449-5","type":"journal-article","created":{"date-parts":[[2022,11,2]],"date-time":"2022-11-02T15:54:38Z","timestamp":1667404478000},"page":"5025-5036","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["OncoTherad\u00ae is an immunomodulator of biological response that downregulate RANK\/RANKL signaling pathway and PD-1\/PD-L1 immune checkpoint in non-muscle invasive bladder cancer"],"prefix":"10.1007","volume":"149","author":[{"given":"Ianny Brum","family":"Reis","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luiz Henrique Soares","family":"Tibo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bianca Ribeiro","family":"de Souza","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nelson","family":"Dur\u00e1n","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wagner Jos\u00e9","family":"F\u00e1varo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,11,2]]},"reference":[{"key":"4449_CR1","first-page":"34","volume":"3","author":"J Aerts","year":"2013","unstructured":"Aerts J, Lievense L, Hoogsteden H, Hegmans J (2013) Immunotherapy prospects in the treatment of lung cancer and mesothelioma. Transl Lung Cancer Res 3:34\u201345","journal-title":"Transl Lung Cancer Res"},{"key":"4449_CR2","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1038\/s41571-018-0095-y","volume":"15","author":"E Ahern","year":"2018","unstructured":"Ahern E, Smyth MJ, Dougall WC, Teng MWL (2018) Roles of the RANKL\u2013RANK axis in antitumour immunity\u2014implications for therapy. Nature Rev Clin Oncol 15:676\u2013693","journal-title":"Nature Rev Clin Oncol"},{"key":"4449_CR3","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1016\/j.immuni.2008.06.015","volume":"29","author":"T Akiyama","year":"2008","unstructured":"Akiyama T, Shimo Y, Yanai H, Qin J, Ohshima D, Maruyama Y et al (2008) The tumor necrosis factor family receptors RANK and CD40 cooperatively establish the thymic medullary microenvironment and self-tolerance. Immunity 29:423\u2013437","journal-title":"Immunity"},{"key":"4449_CR4","doi-asserted-by":"crossref","first-page":"249","DOI":"10.3389\/fimmu.2013.00249","volume":"4","author":"T Akiyama","year":"2013","unstructured":"Akiyama T, Shinzawa M, Qin J, Akiyama N (2013) Regulations of gene expression in medullary thymic epithelial cells required for preventing the onset of autoimmune diseases. Front Immunol 4:249","journal-title":"Front Immunol"},{"unstructured":"American Cancer Society (2021) Overview: bladder cancer. In: What are the key statistics about bladder cancer? American Cancer Society, Atlanta. http:\/\/www.cancer.org\/cancer\/bladdercancer\/detailedguide\/bladder-cancer-key-statistics. Accessed 2 May 2021","key":"4449_CR5"},{"key":"4449_CR6","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/j.eururo.2016.06.010","volume":"71","author":"S Antoni","year":"2017","unstructured":"Antoni S, Ferlay J, Soerjomataram I, Znaor A, Jemal A, Bray F (2017) Bladder cancer incidence and mortality: a global overview and recent trends. Eur Urol 71:96\u2013108","journal-title":"Eur Urol"},{"key":"4449_CR7","doi-asserted-by":"publisher","first-page":"181987","DOI":"10.1155\/2012\/181987","volume":"2012","author":"EJ Askeland","year":"2012","unstructured":"Askeland EJ, Newton MR, O\u2019Donnell MA, Luo Y (2012) Bladder cancer immunotherapy: BCG and beyond. Adv Urol 2012:181987. https:\/\/doi.org\/10.1155\/2012\/181987","journal-title":"Adv Urol"},{"key":"4449_CR8","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1111\/j.1442-2042.1996.tb00490.x","volume":"3","author":"DL Berry","year":"1996","unstructured":"Berry DL, Blumenstein BA, Magyary DL, Lamm DL, Crawford ED (1996) Local toxicity patterns associated with intravesical bacillus Calmette-Guerin: a Southwest Oncology Group study. Int J Urol 3:98\u2013100","journal-title":"Int J Urol"},{"key":"4449_CR9","doi-asserted-by":"crossref","first-page":"2455","DOI":"10.1056\/NEJMoa1200694","volume":"366","author":"JR Brahmer","year":"2012","unstructured":"Brahmer JR, Tykodi SS, Chow LQ, Hwu WJ, Topalian SL, Hwu P et al (2012) Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Eng J Med 366:2455\u20132465","journal-title":"N Eng J Med"},{"key":"4449_CR10","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1038\/nri2061","volume":"7","author":"DJ Campbell","year":"2007","unstructured":"Campbell DJ, Ziegler SF (2007) FOXP3 modifies the phenotypic and functional properties of regulatory T cells. Nature Rev Immunol 7:305\u2013310","journal-title":"Nature Rev Immunol"},{"key":"4449_CR11","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1016\/S1470-2045(13)70277-8","volume":"14","author":"S Chawla","year":"2013","unstructured":"Chawla S, Henshaw R, Seeger L, Choy E, Blay JY, Ferrari S et al (2013) Safety and efficacy of denosumab for adults and skeletally mature adolescents with giant cell tumour of bone: interim analysis of an open-label, parallel-group, phase 2 study. Lancet Oncol 14:901\u2013908","journal-title":"Lancet Oncol"},{"key":"4449_CR12","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1002\/cncr.21978","volume":"107","author":"G Chen","year":"2006","unstructured":"Chen G, Sircar K, Aprikian A, Potti A, Goltzman D, Rabbani SA (2006) Expression of RANK\/RANKL\/OPG in primary and metastatic human prostate cancer as markers of disease stage and functional regulation. Cancer 107:289\u2013298","journal-title":"Cancer"},{"key":"4449_CR13","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1177\/030089161209800612","volume":"98","author":"YB Chen","year":"2012","unstructured":"Chen YB, Mu CY, Huang JA (2012) Clinical significance of programmed death-1 ligand-1 expression in patients with non-small cell lung cancer: a 5-year-follow-up study. Tumori 98:751\u2013755","journal-title":"Tumori"},{"key":"4449_CR14","doi-asserted-by":"crossref","first-page":"329","DOI":"10.3389\/fonc.2013.00329","volume":"3","author":"ML Cheng","year":"2014","unstructured":"Cheng ML, Fong L (2014) Effects of RANKL-targeted therapy in immunity and cancer. Front Oncol 3:329","journal-title":"Front Oncol"},{"key":"4449_CR15","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1111\/j.1600-0714.2009.00793.x","volume":"38","author":"FH Chuang","year":"2009","unstructured":"Chuang FH, Hsue SS, Wu CW, Chen YK (2009) Immunohistochemical expression of RANKL, RANK, and OPG in human oral squamous cell carcinoma. J Oral Pathol Med 38:753\u2013758","journal-title":"J Oral Pathol Med"},{"key":"4449_CR16","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1111\/his.12996","volume":"69","author":"IA Cree","year":"2016","unstructured":"Cree IA, Booton R, Cane P, Gosney J, Ibrahim M, Kerr K et al (2016) PD-L1 testing for lung cancer in the UK: recognizing the challenges for implementation. Histopathology 69:177\u2013186 (Erratum in: Histopathology (2017). 70:318)","journal-title":"Histopathology"},{"issue":"5","key":"4449_CR90","doi-asserted-by":"publisher","first-page":"350","DOI":"10.1016\/j.cllc.2016.03.011","volume":"17","author":"YK Chae","year":"2005","unstructured":"Chae YK, Pan A, Davis AA, Raparia K, Mohindra NA, Matsangou M, Giles FJ  (2016) Biomarkers for PD-1\/PD-L1 Blockade Therapy in\u00a0Non\u2013Small-cell Lung Cancer: Is PD-L1 Expression a Good Marker for Patient Selection?. Clinical Lung Cancer 17(5): 350\u2013361. https:\/\/doi.org\/10.1016\/j.cllc.2016.03.011","journal-title":"Clinical Lung Cance"},{"key":"4449_CR17","doi-asserted-by":"publisher","first-page":"932451","DOI":"10.1155\/2011\/932451","volume":"2011","author":"E David","year":"2011","unstructured":"David E, Blanchard F, Heymann MF, De Pinieux G, Gouin F, R\u00e9dini F et al (2011) The bone niche of chondrosarcoma: a sanctuary for drug resistance, tumour growth and also a source of new therapeutic targets sarcoma. Sarcoma 2011:932451. https:\/\/doi.org\/10.1155\/2011\/932451","journal-title":"Sarcoma"},{"key":"4449_CR18","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1186\/s40364-017-0093-8","volume":"5","author":"LP Diggs","year":"2017","unstructured":"Diggs LP, Hsueh EC (2017) Utility of PD-L1 immunohistochemistry assays for predicting PD-1\/PD-L1 inhibitor response. Biomark Res 5:12","journal-title":"Biomark Res"},{"key":"4449_CR19","doi-asserted-by":"crossref","first-page":"2233","DOI":"10.1016\/j.ejca.2013.02.015","volume":"49","author":"RA Droeser","year":"2013","unstructured":"Droeser RA, Hirt C, Viehl CT, Frey DM, Nebiker C, Huber X et al (2013) Clinical impact of programmed cell death ligand 1 expression in colorectal cancer. Eur J Cancer 49:2233\u20132242","journal-title":"Eur J Cancer"},{"key":"4449_CR20","doi-asserted-by":"crossref","first-page":"012018","DOI":"10.1088\/1742-6596\/1323\/1\/012018","volume":"1323","author":"N Dur\u00e1n","year":"2019","unstructured":"Dur\u00e1n N, Dias QC, F\u00e1varo WJ (2019) OncoTherad: A new nanobiological response modifier, its toxicological and anticancer activities. J Phys Conf Ser 1323:012018","journal-title":"J Phys Conf Ser"},{"key":"4449_CR21","first-page":"2859","volume":"75","author":"LA Emens","year":"2015","unstructured":"Emens LA, Braiteh FS, Cassier P, Delord J-P, Eder JP, Fasso M et al (2015) Inhibition of PD-L1 by MPDL3280A leads to clinical activity in patients with metastatic triple-negative breast cancer. Ann Meet Amer Ass Cancer Res 75(15 Suppl): 2859.","journal-title":"Ann Meet Amer Ass Cancer Res"},{"key":"4449_CR22","first-page":"15","volume":"37","author":"WJ F\u00e1varo","year":"2019","unstructured":"F\u00e1varo WJ, Iantas SR, Gon\u00e7alves JM, Dias QC, Reis IB, Billis A, Dur\u00e1n N, Alonso JC (2019) Role of OncoTherad immunotherapy in the regulation of toll-like receptors-mediated immune system and RANK\/RANKL signaling: New therapeutic perspective for non-muscle invasive bladder cancer. J Clin Oncol 37:15","journal-title":"J Clin Oncol"},{"unstructured":"F\u00e1varo WJ, Dur\u00e1n N (2020) A method for producing a nanostructured complex (cfi-1), a protein associated nanostructured complex (mrb-cfi-1) and use. US Patent App 16\/617,493","key":"4449_CR23"},{"key":"4449_CR24","doi-asserted-by":"crossref","first-page":"2784","DOI":"10.1182\/blood.V98.9.2784","volume":"98","author":"P Fiumara","year":"2001","unstructured":"Fiumara P, Snell V, Li Y, Mukhopadhyay A, Younes M, Gillenwater AM, Cabanillas F et al (2001) Functional expression of receptor activator of nuclear factor kappaB in Hodgkin disease cell lines. Blood 98:2784\u20132790","journal-title":"Blood"},{"key":"4449_CR25","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1038\/ni904","volume":"4","author":"JD Fontenot","year":"2003","unstructured":"Fontenot JD, Gavin MA, Rudensky AY (2003) Foxp3 programs the development and function of CD4+CD25+ regulatory T cells. Nature Immunol 4:330\u2013336","journal-title":"Nature Immunol"},{"key":"4449_CR26","doi-asserted-by":"crossref","first-page":"3015","DOI":"10.1084\/jem.20090847","volume":"206","author":"LM Francisco","year":"2009","unstructured":"Francisco LM, Salinas VH, Brown KE, Vanguri VK, Freeman GJ, Kuchroo VK et al (2009) PD-L1 regulates the development, maintenance, and function of induced regulatory T cells. J Exp Med 206:3015\u20133029","journal-title":"J Exp Med"},{"key":"4449_CR27","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.critrevonc.2019.03.012","volume":"138","author":"S Frega","year":"2019","unstructured":"Frega S, Maso AD, Ferro A, Bonanno L, Conte DF, Passelo G (2019) Heterogeneous tumor features and treatment outcome between males and females with lung cancer (LC): do gender and sex matter? Crit Rev Oncol\/hematol 138:87\u2013103","journal-title":"Crit Rev Oncol\/hematol"},{"key":"4449_CR28","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/j.critrevonc.2016.02.001","volume":"100","author":"S Gandini","year":"2016","unstructured":"Gandini S, Massi D, Mandal\u00e0 M (2016) PD-L1 expression in cancer patients receiving anti PD-1\/PD-L1 antibodies: a systematic review and meta-analysis. Crit Rev Oncol Hematol 100:88\u201398","journal-title":"Crit Rev Oncol Hematol"},{"key":"4449_CR29","first-page":"4427","volume":"8","author":"PV Garcia","year":"2015","unstructured":"Garcia PV, Apolin\u00e1rio LM, B\u00f6ckelmann PK, Nunes IS, Dur\u00e1n N, F\u00e1varo WJ (2015) Alterations in ubiquitin ligase Siah-2 and its corepressor N-CoR after P-MAPA immunotherapy and anti-androgen therapy: new therapeutic opportunities for non-muscle invasive bladder cancer. Int J Clin Exp Pathol 8:4427\u20134443","journal-title":"Int J Clin Exp Pathol"},{"key":"4449_CR30","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.ctrv.2017.10.010","volume":"62","author":"AF Groot","year":"2018","unstructured":"Groot AF, Appelman-Dijkstra NM, Van der Burg SH, Kroep JR (2018) The anti-tumor effect of RANKL inhibition in malignant solid tumors\u2013a systematic review. Cancer Treat Rev 62:18\u201328","journal-title":"Cancer Treat Rev"},{"key":"4449_CR31","doi-asserted-by":"crossref","first-page":"2314","DOI":"10.1016\/j.juro.2007.09.003","volume":"178","author":"MC Hall","year":"2007","unstructured":"Hall MC, Chang SS, Dalbagni G, Prudrakethi RS, Seigne JD, Skinner EC et al (2007) Guideline for the management of nonmuscle invasive bladder c\u00e2ncer (stages Ta, T1, and Tis): 2007 update. J Urol 178:2314\u20132330","journal-title":"J Urol"},{"key":"4449_CR32","doi-asserted-by":"crossref","first-page":"3360","DOI":"10.1073\/pnas.0611533104","volume":"104","author":"J Hamanishi","year":"2007","unstructured":"Hamanishi J, Mandai M, Iwasaki M, Okazaki T, Tanaka Y, Yamaguchi K et al (2007) Programmed cell death 1 ligand 1 and tumor-infiltrating CD8+ T lymphocytes are prognostic factors of human ovarian cancer. Proc Natl Acad Sci USA 104:3360\u20133365","journal-title":"Proc Natl Acad Sci USA"},{"key":"4449_CR33","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.ygyno.2019.04.202","volume":"154","author":"J Hamanishi","year":"2019","unstructured":"Hamanishi J, Murakami R, Baba T, Yamaguchi K, Abiko K, Mandai M (2019) Passenger fusion genes are correlated to antitumor effect of anti-PD-1 antibody nivolumab for ovarian cancer. Gynecol Oncol 154:86","journal-title":"Gynecol Oncol"},{"key":"4449_CR34","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1038\/nature14011","volume":"515","author":"RS Herbst","year":"2014","unstructured":"Herbst RS, Soria JC, Kowanetz M, Fine GD, Hamid O, Gordon MS et al (2014) Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients. Nature 515:563\u2013567","journal-title":"Nature"},{"key":"4449_CR35","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.regpep.2008.02.004","volume":"148","author":"MF Heymann","year":"2008","unstructured":"Heymann MF, Riet A, Le Goff B, Battaglia S, Paineau J, Heymann D (2008) OPG, RANK and RANK ligand expression in thyroid lesions. Regul Pept 148:46\u201353","journal-title":"Regul Pept"},{"key":"4449_CR36","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1056\/NEJMoa1003466","volume":"363","author":"FS Hodi","year":"2010","unstructured":"Hodi FS, O\u2019Day SJ, Weber MDF, RW, Sosman JA, Haanen JB, et al (2010) Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 363:711\u2013723","journal-title":"N Engl J Med"},{"key":"4449_CR37","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1126\/science.1079490","volume":"299","author":"S Hori","year":"2003","unstructured":"Hori S, Nomura T, Sakaguchi S (2003) Control of regulatory T cell development by the transcription factor Foxp3. Science 299:1057\u20131061","journal-title":"Science"},{"key":"4449_CR38","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1007\/s10549-014-3049-9","volume":"146","author":"H Hu","year":"2014","unstructured":"Hu H, Wang J, Gupta A, Shidfar A, Branstetter D, Lee O et al (2014) RANKL expression in normal and malignant breast tissue responds to progesterone and is up-regulated during the luteal phase. Breast Cancer Res Treat 146:515\u2013523","journal-title":"Breast Cancer Res Treat"},{"key":"4449_CR39","volume":"11","author":"M Iria","year":"2021","unstructured":"Iria M (2021) RANK signaling in the differentiation and regeneration of thymic epithelial cells. Front Immunol 11:623265","journal-title":"Front Immunol"},{"key":"4449_CR40","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1097\/MOU.0000000000000753","volume":"30","author":"V Jahrreiss","year":"2020","unstructured":"Jahrreiss V, Pradere B, Laukhtina E, Mori K, Shariat SF (2020) Catalog of exogenous risk factors for bladder carcinogenesis. Curr Opin Urol 30:449\u2013456","journal-title":"Curr Opin Urol"},{"key":"4449_CR41","first-page":"255","volume":"1865","author":"VS Jones","year":"2016","unstructured":"Jones VS, Huang RY, Chen LP, Chen ZS, Fu L, Huang RP (2016) Cytokines in cancer drug resistance: cues to new therapeutic strategies. Biochim Biophys Acta 1865:255\u2013265","journal-title":"Biochim Biophys Acta"},{"key":"4449_CR42","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1038\/nrurol.2017.16","volume":"14","author":"AM Kamat","year":"2017","unstructured":"Kamat AM, Colombel M, Sundi D, Lamm D, Boehle A, Brausi M et al (2017) BCG-unresponsive non-muscle-invasive bladder cancer: recommendations from the IBCG. Nat Rev Urol 14:244\u2013255","journal-title":"Nat Rev Urol"},{"key":"4449_CR43","doi-asserted-by":"crossref","first-page":"249","DOI":"10.5858\/arpa.2015-0303-SA","volume":"140","author":"KM Kerr","year":"2016","unstructured":"Kerr KM, Nicolson MC (2016) Non-small cell lung cancer, PD-L1, and the pathologist. Arch Pathol Lab Med 140:249\u2013254","journal-title":"Arch Pathol Lab Med"},{"issue":"10","key":"4449_CR89","doi-asserted-by":"publisher","first-page":"3474","DOI":"10.1182\/blood-2005-03-1327","volume":"106","author":"TJ Kemp","year":"2005","unstructured":"Kemp TJ, Ludwig AT, Earel JK, JiM Moore, VanOosten RL, Moses B, Kevin L, Nauseef WM, Griffith TS (2005) Neutrophil stimulation with Mycobacterium bovis bacillus Calmette-Gue\u0301rin (BCG) results in the release of functional soluble TRAIL\/Apo-2L. Blood 106(10):3474\u20133482. https:\/\/doi.org\/10.1182\/blood-2005-03-1327","journal-title":"Blood"},{"key":"4449_CR44","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1038\/ni909","volume":"4","author":"R Khattri","year":"2003","unstructured":"Khattri R, Cox T, Yasayko SA, Ramsdell F (2003) An essential role for Scurfin in CD4+CD25+ T regulatory cells. Nature Immunol 4:337\u2013342","journal-title":"Nature Immunol"},{"key":"4449_CR45","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1038\/16852","volume":"397","author":"YY Kong","year":"1999","unstructured":"Kong YY, Yoshida H, Sarosi I, Tan HL, Timms E, Capparelli C et al (1999) OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph-node organogenesis. Nature 397:315\u2013323","journal-title":"Nature"},{"key":"4449_CR46","doi-asserted-by":"publisher","DOI":"10.1016\/s1470-2045(20)30586-6","author":"GS Kulkarni","year":"2020","unstructured":"Kulkarni GS (2020) Nadofaragene firadenovec: a new gold standard for BCG-unresponsive bladder cancer? Lancet Oncol. https:\/\/doi.org\/10.1016\/s1470-2045(20)30586-6","journal-title":"Lancet Oncol"},{"key":"4449_CR47","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1002\/pbc.22720","volume":"56","author":"JA Lee","year":"2011","unstructured":"Lee JA, Jung JS, Kim DH, Lim JS, Kim MS, Kong CB et al (2011) RANKL expression is related to treatment outcome of patients with localized, high-grade osteosarcoma. Pediatr Blood Cancer 56:738\u2013743","journal-title":"Pediatr Blood Cancer"},{"key":"4449_CR48","doi-asserted-by":"crossref","first-page":"2605","DOI":"10.3892\/or.2014.3511","volume":"32","author":"X Li","year":"2014","unstructured":"Li X, Liu Y, Wu B, Dong Z, Wang Y, Lu J et al (2014) Potential role of the OPG\/RANK\/RANKL axis in prostate cancer invasion and bone metastasis. Oncol Rep 32:2605\u20132611","journal-title":"Oncol Rep"},{"key":"4449_CR49","doi-asserted-by":"crossref","first-page":"784","DOI":"10.7150\/jca.14549","volume":"7","author":"Z Li","year":"2016","unstructured":"Li Z, Dong P, Ren M, Song Y, Qiang X, Yang Y et al (2016) PD-L1 expression is associated with tumor FOXP3+ regulatory T-cell infiltration of breast cancer and poor prognosis of patient. J Cancer 7:784\u2013793","journal-title":"J Cancer"},{"key":"4449_CR50","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1186\/s12943-020-01234-1","volume":"19","author":"C Li","year":"2020","unstructured":"Li C, Jiang P, Wei S, Xu X, Wang J (2020) Regulatory T cells in tumor microenvironment: new mechanisms, potential therapeutic strategies and future prospects. Mol Cancer 19:116","journal-title":"Mol Cancer"},{"key":"4449_CR51","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.3389\/fonc.2020.01283","volume":"10","author":"J Ming","year":"2020","unstructured":"Ming J, Cronin SJF, Penninger JM (2020) Targeting the RANKL\/RANK\/OPG axis for cancer therapy. Front Oncol 10:1283","journal-title":"Front Oncol"},{"key":"4449_CR52","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1016\/j.bone.2006.11.006","volume":"40","author":"K Mori","year":"2006","unstructured":"Mori K, Le Goff B, Charrier C, Battaglia S, Heymann D, R\u00e9dini F (2006) DU145 human prostate cancer cells express functional receptor activator of NFkappa B: new insights in the prostate cancer bone metastasis process. Bone 40:981\u2013890","journal-title":"Bone"},{"key":"4449_CR53","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1002\/path.2140","volume":"11","author":"K Mori","year":"2007","unstructured":"Mori K, Le Goff B, Berreur M, Riet A, Moreau A, Blanchard F et al (2007) Human osteosarcoma cells express functional receptor activator of nuclear factor-kappa B. J Pathol 11:555\u2013562","journal-title":"J Pathol"},{"key":"4449_CR54","doi-asserted-by":"crossref","first-page":"261","DOI":"10.3389\/fimmu.2012.00261","volume":"3","author":"CG Mueller","year":"2012","unstructured":"Mueller CG, Hess E (2012) Emerging functions of RANKL in lymphoid tissues. Front Immunol 3:261","journal-title":"Front Immunol"},{"issue":"1","key":"4449_CR91","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1007\/s10549-014-2988-5","volume":"146","author":"S Muenst","year":"2014","unstructured":"Muenst S, Schaerli AR, Gao  F, D\u00e4ster S, Trella E,  Droeser RA,  Muraro MG, Zajac P, Zanetti R, Gillanders WE, Weber WP, Soysal  SD (2014) Expression of programmed death ligand 1 (PD-L1) is associated with poor prognosis in human breast cancer. Breast Cancer Research and Treatment 146(1):15\u201324. https:\/\/doi.org\/10.1007\/s10549-014-2988-5","journal-title":"Breast Cancer Research and Treatment"},{"key":"4449_CR55","doi-asserted-by":"crossref","first-page":"615","DOI":"10.3892\/or.2012.1822","volume":"28","author":"XY Ni","year":"2012","unstructured":"Ni XY, Sui HX, Liu Y, Ke SZ, Wang YN, Gao FG (2012) TGF-beta of lung cancer microenvironment upregulates B7H1 and GITRL expression in dendritic cells and is associated with regulatory T cell generation. Oncol Rep 28:615\u2013621","journal-title":"Oncol Rep"},{"key":"4449_CR56","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1002\/jso.23737","volume":"110","author":"HS Park","year":"2014","unstructured":"Park HS, Lee A, Chae BJ, Bae JS, Song BJ, Jung SS (2014) Expression of receptor activator of nuclear factor kappa-B as a poor prognostic marker in breast cancer. J Surg Oncol 110:807\u2013812","journal-title":"J Surg Oncol"},{"key":"4449_CR57","first-page":"3565","volume":"25","author":"FG Perabo","year":"2005","unstructured":"Perabo FG, Willert PL, Wirger A, Schmidt DH, Von Ruecker A, Mueller SC (2005) Superantigen-activated mononuclear cells induce apoptosis in transitional cell carcinoma. Anticancer Res 25:3565\u20133573","journal-title":"Anticancer Res"},{"key":"4449_CR58","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1007\/s10549-014-2955-1","volume":"145","author":"BM Pfitzner","year":"2014","unstructured":"Pfitzner BM, Branstetter D, Loibl S, Denkert C, Lederer B, Schmitt WD et al (2014) RANK expression as a prognostic and predictive marker in breast cancer. Breast Cancer Res Treat 145:307\u2013315","journal-title":"Breast Cancer Res Treat"},{"key":"4449_CR59","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1038\/nature13904","volume":"515","author":"T Powles","year":"2014","unstructured":"Powles T, Eder JP, Fine GD, Braiteh FS, Loriot Y, Cruz C et al (2014) MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer. Nature 515:558\u2013562","journal-title":"Nature"},{"key":"4449_CR60","doi-asserted-by":"crossref","first-page":"7259","DOI":"10.1021\/acsnano.7b03197","volume":"7","author":"H Quiao","year":"2017","unstructured":"Quiao H, Cui Z, Yang S, Ju D, Wang Y, Yang Y, Han X, Fan Q, Qin A, Wang T, He XP, Bu W, Tang T (2017) Targeting osteocytes to attenuate early breast cancer bone metastasis by theranostic upconversion nanoparticles with responsive plumbagin release. ACS Nano 7:7259\u20137273","journal-title":"ACS Nano"},{"key":"4449_CR61","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1186\/s13000-016-0545-8","volume":"11","author":"MC Rebelatto","year":"2016","unstructured":"Rebelatto MC, Midha A, Mistry A, Sabalos C, Schechter N, Li X et al (2016) Development of a programmed cell death ligand-1 immunohistochemical assay validated for analysis of non-small cell lung cancer and head and neck squamous cell carcinoma. Diagn Pathol 11:95","journal-title":"Diagn Pathol"},{"key":"4449_CR62","first-page":"71762","volume":"76","author":"IB Reis","year":"2022","unstructured":"Reis IB, Tibo LHS, Socca EAR, Souza BR, Dur\u00e1n N, F\u00e1varo WJ (2022a) OncoTherad\u00ae (MRB-CFI-1) nano-immunotherapy reduced tumoral progression in non-muscle invasive bladder cancer through activation of Toll-like signaling pathway. Tissue Cell 76:71762","journal-title":"Tissue Cell"},{"key":"4449_CR63","first-page":"01747","volume":"75","author":"SK Reis","year":"2022","unstructured":"Reis SK, Socca EAR, de Souza BR, Genaro SC, Dur\u00e1n N, F\u00e1varo WJ (2022b) Effects of combined OncoTherad immunotherapy and probiotic supplementation on modulating the chronic inflammatory process in colorectal carcinogenesis. Tissue Cell 75:01747","journal-title":"Tissue Cell"},{"key":"4449_CR64","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1042\/BSR20160150","volume":"36","author":"N Renema","year":"2016","unstructured":"Renema N, Navet B, Heymann MF, Lezot F, Heymann D (2016) RANK-RANKL signalling in cancer. Biosci Rep 36:1\u201318","journal-title":"Biosci Rep"},{"key":"4449_CR65","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1056\/NEJMoa1412690","volume":"372","author":"C Robert","year":"2015","unstructured":"Robert C, Karaszewska B, Schachter J, Rutkowski P, Mackiewicz A, Stroiakovski D et al (2015) Improved overall survival in melanoma with combined dabrafenib and trametinib. N Engl J Med 372:30\u201339","journal-title":"N Engl J Med"},{"key":"4449_CR66","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1016\/j.canlet.2020.07.022","volume":"490","author":"R Saleh","year":"2020","unstructured":"Saleh R, Elkord E (2020) FoxP3\u00feT regulatory cells in cancer: Prognostic biomarkers and therapeutic targets. Cancer Lett 490:174\u2013185","journal-title":"Cancer Lett"},{"key":"4449_CR67","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1002\/jcp.22402","volume":"226","author":"D Santini","year":"2011","unstructured":"Santini D, Perrone G, Roato I, Godio L, Pantano F, Grasso D et al (2011a) Expression pattern of receptor activator of NFkB (RANK) in a series of primary solid tumors and related metastases. J Cell Physiol 226:780\u2013784","journal-title":"J Cell Physiol"},{"key":"4449_CR68","doi-asserted-by":"crossref","first-page":"19234","DOI":"10.1371\/journal.pone.0019234","volume":"6","author":"D Santini","year":"2011","unstructured":"Santini D, Schiavon G, Vincenzi B, Gaeta L, Pantano F, Russo A et al (2011b) Receptor activator of NF-kB (RANK) expression in primary tumors associates with bone metastasis occurrence in breast cancer patients. PLoS\u00a0One 6:19234","journal-title":"PLoS\u00a0One"},{"key":"4449_CR69","first-page":"1931","volume":"16","author":"TH Schreiber","year":"2007","unstructured":"Schreiber TH (2007) The use of FoxP3 as a biomarker and prognostic factor for malignant human tumors. Cancer Epidemiol Biomarkers Prev a Publ Am Assoc Cancer Res Cosponsored Am Soc Prev Oncol 16:1931\u20131934","journal-title":"Cancer Epidemiol Biomarkers Prev a Publ Am Assoc Cancer Res Cosponsored Am Soc Prev Oncol"},{"key":"4449_CR70","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1038\/ni1443","volume":"8","author":"AH Sharpe","year":"2007","unstructured":"Sharpe AH, Wherry EJ, Ahmed R, Freeman GJ (2007) The function of programmed cell death 1 and its ligands in regulating autoimmunity and infection. Nature Immunol 8:239\u2013245","journal-title":"Nature Immunol"},{"key":"4449_CR71","doi-asserted-by":"crossref","first-page":"10","DOI":"10.3322\/caac.20138","volume":"62","author":"R Siegel","year":"2012","unstructured":"Siegel R, Naishadham D, Jemal A (2012) Cancer statistics. CA. Cancer J Clin 62:10\u201329","journal-title":"Cancer J Clin"},{"key":"4449_CR72","doi-asserted-by":"crossref","first-page":"7570","DOI":"10.3390\/ijms21207570","volume":"21","author":"A Simatou","year":"2020","unstructured":"Simatou A, Sarantis P, Koustas E, Papavassiliou AG, Karamouzis MV (2020) The role of the RANKL\/RANK axis in the prevention and treatment of breast cancer with immune checkpoint inhibitors and anti-RANKL. Int J Mol Sci 21:7570","journal-title":"Int J Mol Sci"},{"key":"4449_CR73","doi-asserted-by":"crossref","first-page":"3801","DOI":"10.2147\/OTT.S135867","volume":"10","author":"M Sisay","year":"2017","unstructured":"Sisay M, Mengistu G, Edessa D (2017) The RANK\/RANKL\/OPG system in tumorigenesis and metastasis of cancer stem cell: potential targets for anticancer therapy. Onco Targets Ther 10:3801\u20133810","journal-title":"Onco Targets Ther"},{"key":"4449_CR74","doi-asserted-by":"crossref","first-page":"629","DOI":"10.3389\/fimmu.2019.00629","volume":"10","author":"C Sobacchi","year":"2020","unstructured":"Sobacchi C, Menale C, Villa A (2020) The RANKL-RANK axis: a bone to thymus round trip. Front Immunol 10:629\u2013638","journal-title":"Front Immunol"},{"key":"4449_CR75","doi-asserted-by":"crossref","first-page":"129","DOI":"10.4236\/jct.2015.62014","volume":"6","author":"RM Stopglia","year":"2015","unstructured":"Stopglia RM, Matheus WE, Garcia PV, Billis A, Castilho MA, Figueiredo de Jesus VH et al (2015) Molecular assessment of non-muscle invasive and muscle invasive bladder tumors: mapping of putative urothelial stem cells and toll-like receptors (TLR) signaling. J Cancer Ther 6:129\u2013140","journal-title":"J Cancer Ther"},{"key":"4449_CR76","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/j.lungcan.2006.05.012","volume":"53","author":"Y Sun","year":"2006","unstructured":"Sun Y, Wang Y, Zhao J, Gua M, Giscombe R, Lefvert AK et al (2006) B7\u2013H3 and B7\u2013H4 expression in non-small-cell lung cancer. Lung Cancer 53:143\u2013151","journal-title":"Lung Cancer"},{"key":"4449_CR77","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1172\/JCI31405","volume":"117","author":"JB Swann","year":"2007","unstructured":"Swann JB, Smyth MJ (2007) Immune surveillance of tumors. J Clin Invest 117:1137\u20131146","journal-title":"J Clin Invest"},{"key":"4449_CR78","doi-asserted-by":"crossref","first-page":"5064","DOI":"10.1158\/1078-0432.CCR-13-3271","volume":"20","author":"JM Taube","year":"2014","unstructured":"Taube JM, Klein A, Brahmer JR, Xu H, Pan X, Kim JH et al (2014) Association of PD-1, PD-1 ligands, and other features of the tumor immune microenvironment with response to anti-PD-1 therapy. Clin Cancer Res 20:5064\u20135074","journal-title":"Clin Cancer Res"},{"key":"4449_CR79","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1038\/modpathol.2017.156","volume":"31","author":"JM Taube","year":"2018","unstructured":"Taube JM, Galon J, Sholl LM, Rodig SJ, Cottrell TR, Giraldo NA et al (2018) Implications of the tumor immune microenvironment for staging and therapeutics. Mod Pathol 31:214\u2013234","journal-title":"Mod Pathol"},{"key":"4449_CR80","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1016\/j.cytogfr.2004.06.004","volume":"15","author":"S Theoleyre","year":"2004","unstructured":"Theoleyre S, Wittrant Y, KwanTat S, Fortun Y, Redini F, Heymann D (2004) The molecular triad OPG\/RANK\/RANKL: involvement in the orchestration of pathophysiological bone remodeling. Cytokine Growth Factor Rev 15:457\u2013475","journal-title":"Cytokine Growth Factor Rev"},{"key":"4449_CR81","doi-asserted-by":"crossref","first-page":"1813","DOI":"10.3892\/ol.2015.3489","volume":"10","author":"K Trieb","year":"2015","unstructured":"Trieb K, Windhager R (2015) Receptor activator of nuclear factor \u03baB expression is a prognostic factor in human osteosarcoma. Oncol Lett 10:1813\u20131815","journal-title":"Oncol Lett"},{"key":"4449_CR82","doi-asserted-by":"crossref","first-page":"1450","DOI":"10.1038\/nm.3391","volume":"19","author":"L Wan","year":"2013","unstructured":"Wan L, Pantel K, Kang Y (2013) Tumor metastasis: moving new biological insights into the clinic. Nat Med 19:1450\u20131464","journal-title":"Nat Med"},{"key":"4449_CR83","doi-asserted-by":"crossref","first-page":"5023","DOI":"10.2147\/OTT.S105862","volume":"9","author":"X Wang","year":"2016","unstructured":"Wang X, Teng F, Kong L, Yu J (2016) PD-L1 expression in human cancers and its association with clinical outcomes. Onco Targets Ther 9:5023\u20135039","journal-title":"Onco Targets Ther"},{"key":"4449_CR84","first-page":"49","volume":"1704","author":"Y Wittrant","year":"2004","unstructured":"Wittrant Y, Th\u00e9oleyre S, Chipoy C, Padrines M, Blanchard F, Heymann D, R\u00e9dini F (2004) RANKL\/RANK\/OPG: new therapeutic targets in bone tumours and associated osteolysis. Biochim Biophys Acta 1704:49\u201357","journal-title":"Biochim Biophys Acta"},{"key":"4449_CR85","doi-asserted-by":"crossref","first-page":"76","DOI":"10.3389\/fcell.2020.00076","volume":"8","author":"X Wu","year":"2020","unstructured":"Wu X, Li F, Dang L, Liang C, Lu A, Zhang G (2020) RANKL\/RANK system-based mechanism for breast cancer bone metastasis and related therapeutic strategies. Front Cell Dev Biol 8:76","journal-title":"Front Cell Dev Biol"},{"key":"4449_CR86","doi-asserted-by":"crossref","first-page":"1643","DOI":"10.1093\/intimm\/dxh165","volume":"16","author":"H Yagi","year":"2004","unstructured":"Yagi H, Nomura T, Nakamura K, Yamazaki S, Kitawaki T, Hori S et al (2004) Crucial role of FOXP3 in the development and function of human CD25+CD4+ regulatory T cells. Inter Immunol 16:1643\u20131656","journal-title":"Inter Immunol"},{"key":"4449_CR87","doi-asserted-by":"crossref","first-page":"964","DOI":"10.1016\/j.jtho.2016.04.014","volume":"11","author":"H Yu","year":"2016","unstructured":"Yu H, Boyle TA, Zhou C, Rimm DL, Hirsch FR (2016) PD-L1 expression in lung cancer. J Thorac Oncol 11:964\u2013975","journal-title":"J Thorac Oncol"},{"key":"4449_CR88","first-page":"1","volume":"2018","author":"B Zhao","year":"2018","unstructured":"Zhao B, Chang L, Fu H, Sun G, Yang W (2018) The role of autoimmune regulator (AIRE) in peripheral tolerance. J Immunol Res 2018:1\u20136","journal-title":"J Immunol Res"}],"container-title":["Journal of Cancer Research and Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00432-022-04449-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00432-022-04449-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00432-022-04449-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,7,15]],"date-time":"2023-07-15T14:16:09Z","timestamp":1689430569000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00432-022-04449-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11,2]]},"references-count":91,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2023,7]]}},"alternative-id":["4449"],"URL":"https:\/\/doi.org\/10.1007\/s00432-022-04449-5","relation":{},"ISSN":["0171-5216","1432-1335"],"issn-type":[{"type":"print","value":"0171-5216"},{"type":"electronic","value":"1432-1335"}],"subject":[],"published":{"date-parts":[[2022,11,2]]},"assertion":[{"value":"5 September 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 October 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 November 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors report the non-existence of any kind of conflict of interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"It was added in the text.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}]}}